Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Authors:
- Alison E. SmithASAlison E. Smith
- Stacia ChanSCStacia Chan
- Zhiyong WangZWZhiyong Wang
- Asako McCloskeyAMAsako McCloskey
- Quinn ReillyQRQuinn Reilly
- Jayden Z. WangJWJayden Z. Wang
- Hetika Vora. PatelHPHetika Vora. Patel
- Keiichi KoshizukaKKKeiichi Koshizuka
- Harris S. SoiferHSHarris S. Soifer
- Linda KesslerLKLinda Kessler
- Ashley DayoubADAshley Dayoub
- Victoria VillaflorVVVictoria Villaflor
Open Access
- 20 June 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (19) , 3252-3263
Abstract
Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development of rational therapeutic strategies. Toward this end, we targeted the key HNSCC drivers PI3K–mTOR and HRAS via the combination of tipifarnib, a farnesyltransferase (FTase) inhibitor, and alpelisib, a PI3Kα inhibitor, in multiple molecularly defined subsets of HNSCC. Tipifarnib synergized with alpelisib at the level of mTOR in PI3Kα- or HRAS-dependent HNSCCs, leading to marked cytotoxicity in vitro and tumor regression in vivo. On the basis of these findings, the KURRENT-HN trial was launched to evaluate the effectiveness of this combination in PIK3CA-mutant/amplified and/or HRAS-overexpressing R/M HNSCC. Preliminary evidence supports the clinical activity of this molecular biomarker-driven combination therapy. Combined alpelisib and tipifarnib has potential to benefit >45% of patients with R/M HNSCC. By blocking feedback reactivation of mTORC1, tipifarnib may prevent adaptive resistance to additional targeted therapies, enhancing their clinical utility. Significance: The mechanistically designed, biomarker-matched strategy of combining alpelisib and tipifarnib is efficacious in PIK3CA- and HRAS-dysregulated head and neck squamous carcinoma and could improve outcomes for many patients with recurrent, metastatic disease. See related commentary by Lee et al., p. 3162Keywords
All Related Versions
Funding Information
- N/A
This publication has 50 references indexed in Scilit:
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from LongevityScience, 2012
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin SignalingScience, 2011
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancerJournal of Clinical Investigation, 2010
- Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerBreast Cancer Research, 2010
- Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic eventsGenes & Development, 2008
- Tumorigenic activity and therapeutic inhibition of Rheb GTPaseGenes & Development, 2008
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJournal of Clinical Investigation, 2008
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences, 2008